Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27052589 | 0.97 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTKMT2AATM | |
| SCHEMBL27059580 | 0.97 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTKMT2AATM | |
| SCHEMBL27052510 | 0.84 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2AATMLMNA | |
| SCHEMBL27105745 | 0.82 | MAPT (0.48) | ALDH1A1SMN1; SMN2MAPTLMNAGAA | |
| SCHEMBL27052249 | 0.82 | MAPT (0.48) | ALDH1A1SMN1; SMN2MAPTLMNAGAA | |
| SCHEMBL27052939 | 0.82 | ALDH1A1 (0.43) | ALDH1A1MAPTKMT2AATMLMNA | |
| SCHEMBL27052161 | 0.82 | CHRNA7 (0.50) | KMT2AATMLMNAGAA | |
| Inositol Niacinate SCHEMBL122591 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MAPTKMT2AATMLMNA | |
| Inositol Niacinate SCHEMBL122590 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MAPTKMT2AATMLMNA | |
| Inositol Niacinate SCHEMBL13557040 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MAPTKMT2AATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067763-A1 | SOLID TITANIUM CATALYST COMPONENT, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMERIZATION METHOD, AND PROPYLENE POLYMER | MITSUI CHEMICALS, INC. (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240025838-A1 | ESTER COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240025838-A1 | ESTER COMPOUND | MITSUI CHEMICALS, INC. (JP) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025838-A1 | ESTER COMPOUND | NR1H3, CYP4A11, H1-4 | ALDH1A1 650/4885SMN1; SMN2 3906/4885MAPT 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.